NasdaqGS - Delayed Quote • USD
Prothena Corporation plc (PRTA)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:20 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 9 | 9 |
| Avg. Estimate | -1.2 | -1.21 | -4.86 | -4.13 |
| Low Estimate | -1.42 | -1.44 | -5.82 | -6.51 |
| High Estimate | -1.09 | -1.12 | -4.38 | -0.49 |
| Year Ago EPS | -0.89 | -1.03 | -2.76 | -4.86 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 9 | 8 |
| Avg. Estimate | 2.17M | 2.17M | 13.35M | 105.31M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 8.75M | 8.75M | 50M | 300M |
| Year Ago Sales | 2.17M | -- | 91.37M | 13.35M |
| Sales Growth (year/est) | 0.00% | -- | -85.40% | 688.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.94 | -1 | -0.32 | -1.22 |
| EPS Actual | -0.89 | -1.03 | 0.38 | -1.26 |
| Difference | 0.05 | -0.03 | 0.7 | -0.04 |
| Surprise % | 5.30% | -3.00% | 218.80% | -3.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.2 | -1.21 | -4.86 | -4.13 |
| 7 Days Ago | -1.2 | -1.21 | -4.86 | -4.13 |
| 30 Days Ago | -1.2 | -1.21 | -4.92 | -4.3 |
| 60 Days Ago | -1.21 | -1.22 | -4.98 | -4.13 |
| 90 Days Ago | -1.34 | -1.4 | -4.47 | -4.02 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | PRTA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -34.80% | -- | -- | 5.40% |
| Next Qtr. | -17.50% | -- | -- | 10.90% |
| Current Year | -76.10% | -- | -- | 4.50% |
| Next Year | 15.00% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 34.07% | -- | -- | 10.94% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight | 4/10/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/13/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 2/20/2024 |
| Maintains | JMP Securities: Market Outperform to Market Outperform | 2/16/2024 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 2/16/2024 |
| Downgrade | B of A Securities: Buy to Neutral | 1/30/2024 |
Related Tickers
DNLI Denali Therapeutics Inc.
15.43
+3.14%
BCYC Bicycle Therapeutics plc
22.73
+0.93%
ACIU AC Immune SA
2.3500
+2.62%
IMCR Immunocore Holdings plc
58.46
+0.79%
KURA Kura Oncology, Inc.
19.65
+3.42%
AVTE Aerovate Therapeutics, Inc.
21.75
+0.83%
PLRX Pliant Therapeutics, Inc.
11.81
-0.59%
IMVT Immunovant, Inc.
27.17
-2.09%
ARVN Arvinas, Inc.
32.37
+2.44%
FDMT 4D Molecular Therapeutics, Inc.
23.25
-1.19%